<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pozelimab: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pozelimab: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Pozelimab: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="142480" href="/d/html/142480.html" rel="external">see "Pozelimab: Drug information"</a> and <a class="drug drug_patient" data-topicid="142503" href="/d/html/142503.html" rel="external">see "Pozelimab: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F58569726"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Serious meningococcal infections:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">Life-threatening and fatal meningococcal infections have occurred in patients treated with complement inhibitors. Meningococcal infection may become rapidly life-threatening or fatal if not recognized and treated early. Complete or update meningococcal vaccination (for serogroups A, C, W and Y, and serogroup B) at least 2 weeks prior to administering the first dose of pozelimab, unless the risks of delaying therapy outweigh the risk of developing a meningococcal infection. Follow the most current Advisory Committee on Immunization Practices (ACIP) recommendations for meningococcal vaccination in patients receiving a complement inhibitor. Patients receiving pozelimab are at increased risk for invasive disease caused by <i>Neisseria meningitidis</i>, even if they develop antibodies following vaccination. Monitor patients for early signs of meningococcal infections and evaluate immediately if infection is suspected.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F58588662"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Veopoz</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F58569903"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Complement C5 Inhibitor</span>;</li>
<li>
<span class="list-set-name">Complement Inhibitor</span>;</li>
<li>
<span class="list-set-name">Monoclonal Antibody</span>;</li>
<li>
<span class="list-set-name">Monoclonal Antibody, Complement Inhibitor</span></li></ul></div>
<div class="block dop drugH1Div" id="F58585993"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety:</b> Vaccinate patient against meningococcal infection at least 2 weeks prior to treatment initiation, according to current recommendations. If urgent therapy is needed in a patient who is not up to date, administer meningococcal vaccines as soon as possible and use antibacterial drug prophylaxis.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5d63f5ac-38b6-4f77-8543-9a899f0add3d">CD55-deficient protein-losing enteropathy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>CD55-deficient protein-losing enteropathy:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Loading dose: IV: 30 mg/kg once on day 1.</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance dose: SUBQ: 10 mg/kg/dose once weekly beginning 7 days after loading dose. If inadequate response after 3 maintenance doses, may increase to 12 mg/kg/dose once weekly. Maximum dose: 800 mg/dose.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for toxicity:</b> Interrupt therapy in patients undergoing treatment for a serious encapsulated bacterial infection (eg, <i>Neisseria meningitidis</i>, <i>Streptococcus pneumoniae</i>) until the infection resolves.</p></div>
<div class="block dorp drugH1Div" id="F58585994"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, pozelimab is not likely to undergo renal excretion.</p></div>
<div class="block dohp drugH1Div" id="F58585995"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, pozelimab is not likely to undergo hepatic excretion.</p></div>
<div class="block doa drugH1Div" id="F58599919"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="142480" href="/d/html/142480.html" rel="external">see "Pozelimab: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5d63f5ac-38b6-4f77-8543-9a899f0add3d">CD55-deficient protein-losing enteropathy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>CD55-deficient protein-losing enteropathy</b>
<b>: Note: </b>Patients must receive meningococcal vaccine at least 2 weeks prior to treatment initiation; revaccinate according to current guidelines. If urgent pozelimab initiation is necessary and vaccination is not up to date with MenACWY and MenB vaccines according to Advisory Committee on Immunization Practices recommendations, vaccinate and provide antibacterial prophylaxis.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Loading dose: IV:</b> 30 mg/kg as a single dose on day 1.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Maintenance dose: SUBQ:</b> 10 mg/kg once weekly starting on day 8; at week 4, dose may be increased to 12 mg/kg once weekly if inadequate clinical response after 3 weekly doses; maximum dose: 800 mg once weekly. <b> Note:</b> Doses &gt;400 mg require 2 SUBQ injections.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Missed maintenance dose</b>:</p>
<p style="text-indent:-2em;margin-left:8em;">≤3 days from the assigned day: Administer the missed dose as soon as possible, then administer the next weekly dose on the regular schedule.</p>
<p style="text-indent:-2em;margin-left:8em;">&gt;3 days from the assigned day: Omit the missed dose, then administer the next weekly dose on the regular schedule.</p>
<p style="text-indent:-2em;margin-left:8em;">The day the weekly dose is administered can be revised at any time as long as 96 hours elapse between doses.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F58599921"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, pozelimab is not likely to undergo renal excretion.</p></div>
<div class="block doha drugH1Div" id="F58599922"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, pozelimab is not likely to undergo hepatic excretion.</p></div>
<div class="block adr drugH1Div" id="F58588720"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in children, adolescents, and adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Increased blood pressure</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Bone fracture</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Upper respiratory tract infection</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased uric acid, metabolic acidosis</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Gingival hemorrhage</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Hematuria, proteinuria</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased liver enzymes</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection-site reaction (including dermatitis and erythema at injection site)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Infection: Meningococcal infection</p></div>
<div class="block coi drugH1Div" id="F58569731"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Patients with unresolved <i>N. meningitidis</i> infection.</p></div>
<div class="block war drugH1Div" id="F58599908"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Infections: Pozelimab blocks terminal complement activation and therefore may increase the risk for susceptibility to bacterial infections, especially encapsulated bacteria, such as infections caused by <i>Neisseria meningitidis </i>but also <i>Streptococcus pneumoniae, Haemophilus influenzae, </i>and, to a lesser extent, <i>Neisseria gonorrhoeae. </i>Patients receiving pozelimab may be at increased risk for serious <i>S. pneumoniae</i> and <i>H. influenzae</i> type b (Hib) infections; vaccinate for <i>S. pneumoniae</i> and Hib according to the Advisory Committee on Immunization Practices (ACIP) recommendations. Therapy should be interrupted in patients undergoing treatment for a serious encapsulated bacterial infection until the infection resolves. Educate patients on the risks and prevention strategies for gonorrhea.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infusion reactions: Administration of pozelimab may result in infusion reactions, including anaphylaxis and hypersensitivity. If signs of cardiovascular instability or respiratory compromise occur, interrupt therapy and manage supportively.</p>
<p style="text-indent:-2em;margin-left:4em;">• Meningococcal infections: Life-threatening and fatal meningococcal infections have been reported in vaccinated and unvaccinated patients treated with complement inhibitors. The use of pozelimab increases susceptibility to serious meningococcal infections (septicemia and/or meningitis). Meningococcal disease due to any serogroup may occur. Complete or update meningococcal vaccination (serogroups A, C, W, Y and B) at least 2 weeks prior to the first dose of pozelimab. If urgent pozelimab therapy is indicated in an unvaccinated patient, administer meningococcal vaccine(s) as soon as possible and provide antibacterial prophylaxis. Infection can be caused by nongroupable strains of <i>N. meningitidis; </i>therefore, vaccination does not eliminate the risk of infection despite presence of antibodies following vaccination. Educate patients on signs/symptoms of meningitis and steps necessary to seek immediate medical care. Consider pozelimab discontinuation in patients who are undergoing treatment for serious meningococcal infection. Revaccinate for meningococcal disease according to ACIP recommendations, taking the duration of pozelimab therapy into consideration.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concurrent drug therapy issues:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Immune complex formation: Transition between complement inhibitors has resulted in immune complex formation leading to a decrease in drug concentration and symptoms consistent with hypersensitivity reactions. Immune complex formation has not been observed with switching to pozelimab.</p></div>
<div class="block prod-avail drugH1Div" id="F58569725"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Veopoz: FDA approved August 2023; availability anticipated in 2023.</p></div>
<div class="block foc drugH1Div" id="F58588663"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Veopoz: Pozelimab-bbfg 400 mg/2 mL (2 mL) [contains polysorbate 80]</p></div>
<div class="block geq drugH1Div" id="F58588661"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F58659621"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Veopoz Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">400 mg/2 mL (per mL): $20,769.23</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block admp drugH1Div" id="F58588717"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral:</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>IV infusion (loading dose only):</i> Infuse IV through a 0.2- to 5-micron filter over at least 1 hour; maximum rate: 1,000 mg/hour. If stored in refrigerator, allow to reach room temperature prior to administration. Infusion should be completed within 8 hours of preparation if not refrigerated or 24 hours if refrigerated after preparation. Observe patient for 30 minutes following infusion completion.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Subcutaneous injection (maintenance doses):</i> Administer SUBQ into abdomen, thigh, or upper arm. Rotate injection sites and avoid injecting into moles, scars, or areas that are tender, bruised, red, scaly, hard, or not intact. If multiple injections are required for a single dose (ie, doses &gt;400 mg), administer each injection at a different injection site. Observe patient for 30 minutes after completion of first SUBQ injection.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Missed maintenance dose:</i> If it has been ≤3 days since dose was missed, administer as soon as possible, then resume regular once-weekly schedule. If &gt;3 days since missed dose, skip dose and administer next dose on regularly scheduled day. Do not administer 2 doses on the same day. The day of weekly dose can change as long as there are ≥4 days (96 hours) between doses.</p></div>
<div class="block adm drugH1Div" id="F58599924"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Prior to infusion, allow the diluted solution to warm to room temperature if refrigerated. Infuse through IV line that contains a 0.2- to 5-micron filter over a minimum of 1 hour; infusion rate should not exceed 1 g/hour. Do not administer other medications through the same IV line.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>SUBQ:</b> Administer dose into the abdomen, thigh, or upper arm. Rotate injection sites; do not administer into moles, scars, or areas where the skin is tender, bruised, red, hard, or not intact. Doses &gt;400 mg should be separated into 2 injections administered at different sites.</p></div>
<div class="block sts drugH1Div" id="F58599910"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Store intact vial at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do not freeze.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Store diluted solution at room temperature up to 25°C (77°F) for no more than 8 hours (including infusion time) or between 2°C to 8°C (36°F to 46°F) for no more than 24 hours (including infusion time). Do not freeze.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>SUBQ:</b> Administer within 4 hours of preparation.</p></div>
<div class="block meg drugH1Div" id="F58698733"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Veopoz: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F761339s000lbl.pdf%23page%3D16&amp;token=ir8kNhwyLurnUUmP4XuPuRPCeo%2F9rkkfrvyblqD5hpe%2BzVdGPbn%2Bn5X%2B%2FQJ3HmWlMF1p7rHQKAPVBuYs57gs%2BnAryxjh8I1TDs1%2BM7gxyk0q3J2wmxMAbWBnCvplq%2FLx&amp;TOPIC_ID=142530" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761339s000lbl.pdf#page=16</a></p></div>
<div class="block usep drugH1Div" id="F58569904"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of CD55-deficient protein-losing enteropathy, also known as CHAPLE disease (FDA approved in ages ≥1 year and adults).</p></div>
<div class="block cyt drugH1Div" id="F58612009"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F58612006"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of immunosuppressive therapy is reduced. Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing therapeutic immunosuppressants several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Denosumab.  Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Efgartigimod Alfa: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Globulin: May diminish the therapeutic effect of Pozelimab. Management: Avoid concurrent use of intravenous immunoglobulin with pozelimab. If the combination cannot be avoided, monitor for evidence of a diminished effect of pozelimab and worsening underlying disease.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Pimecrolimus. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rozanolixizumab: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Tofacitinib.  Management: Coadministration of tofacitinib with potent immunosuppressants is not recommended. Use with non-biologic disease-modifying antirheumatic drugs (DMARDs) was permitted in psoriatic arthritis clinical trials.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F58599906"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events were not observed in animal reproduction studies.</p>
<p style="text-indent:0em;margin-top:2em;">Pozelimab is a humanized monoclonal antibody (IgG<sub>4</sub>). Human IgG crosses the placenta. Fetal exposure is dependent upon the IgG subclass, maternal serum concentrations, placental integrity, newborn birth weight, and GA, generally increasing as pregnancy progresses. The lowest exposure would be expected during the period of organogenesis and the highest during the third trimester (Clements 2020; Palmeira 2012; Pentsuk 2009).</p></div>
<div class="block mopp drugH1Div" id="F58588718"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor for signs/symptoms of meningococcal disease; regular gonorrhea testing (for sexually active patients). Monitor for hypersensitivity reactions; observe for 30 minutes after end of IV loading dose and after the first SUBQ injection.</p></div>
<div class="block pha drugH1Div" id="F58599912"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Pozelimab-bbfg is a human, monoclonal immunoglobulin G4P (IgG4P ) antibody directed against the terminal complement protein C5 that inhibits terminal complement activation by blocking cleavage of C5 into C5a (anaphylatoxin) and C5b, thereby blocking the formation of the membrane-attack complex (C5b-C9, a structure mediating cell lysis).</p></div>
<div class="block phk drugH1Div" id="F58599913"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 3.3 L (following 30 mg/kg IV); 8.6 L (following 600 mg SUBQ).</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Degraded into small particles and amino acids through catabolic pathways similar to endogenous IgG.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: 51% (following 600 mg SUBQ).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 13.5 days (following 30 mg/kg IV); 14.1 days (following 600 mg SUBQ).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: 7 days.</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-33956488">
<a name="33956488"></a>Anderson PO. Monoclonal antibodies during breastfeeding. <i>Breastfeed Med</i>. 2021;16(8):591-593. doi:10.1089/bfm.2021.0110<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pozelimab-pediatric-drug-information/abstract-text/33956488/pubmed" id="33956488" target="_blank">33956488</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33013843">
<a name="33013843"></a>Clements T, Rice TF, Vamvakas G, et al. Update on transplacental transfer of IgG subclasses: impact of maternal and fetal factors. <i>Front Immunol</i>. 2020;11:1920. doi:10.3389/fimmu.2020.01920<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pozelimab-pediatric-drug-information/abstract-text/33013843/pubmed" id="33013843" target="_blank">33013843</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22235228">
<a name="22235228"></a>Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. <i>Clin Dev Immunol</i>. 2012;2012:985646. doi:10.1155/2012/985646<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pozelimab-pediatric-drug-information/abstract-text/22235228/pubmed" id="22235228" target="_blank">22235228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19626656">
<a name="19626656"></a>Pentsuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. <i>Birth Defects Res B Dev Reprod Toxicol</i>. 2009;86(4):328-344. doi:10.1002/bdrb.20201<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pozelimab-pediatric-drug-information/abstract-text/19626656/pubmed" id="19626656" target="_blank">19626656</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Veopoz.1">
<a name="Veopoz.1"></a>Veopoz (pozelimab-bbfg) [prescribing information]. Tarrytown, NY: Regeneron Pharmaceuticals Inc; August 2023.</div>
</li></ol></div><div id="topicVersionRevision">Topic 142530 Version 11.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
